Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.
Location: United States
Employees: 11-50
Total raised: $50M
Investors 1
| Date | Name | Website |
| 31.12.2022 | Alta Partn... | altapartne... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.04.2022 | Series A | $50M | Alta Partn... |
Mentions in press and media 6
| Date | Title | Description |
| 26.05.2026 | Lilly goes on $20 billion buying spree as company seeks next act | Getting your Trinity Audio player ready... By Madison Muller, Gerry Smith, Bloomberg News Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond ... |
| 20.04.2026 | - | Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary ... |
| 15.03.2024 | Learn how Developments in Genetic Medicine are Improving Treatment of Cancer | medical advancements Discover the latest innovations in therapeutic technology on an upcoming segment of Advancements. JUPITER, Fla., March 15, 2024 /PRNewswire-PRWeb/ -- Advancements with Ted Danson is excited to announce a new segment fea... |
| 02.05.2022 | Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines | What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines. – Despite life-changing respon... |
| 29.04.2022 | Kelonia Therapeutics Raises $50M in Series A Financing | Kelonia Therapeutics, a Boston, MA-based biotech company focused on in vivo gene delivery, raised $50m in Series A financing. Backers included Alta Partners, Horizons Ventures, Venrock and other investors. The company will use the funding t... |
| 28.04.2022 | Has Elon Musk already broken his merger agreement with Twitter? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Elon Musk has been tweeting this week in reference to the Twitter deal—which is, in fact, allowed... |